Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies (Q36849432)

16 August 2017

title

Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies (English)

1 reference

16 August 2017

author name string

Carlos Rodríguez-Galindo

1

1 reference

16 August 2017

Tiebin Liu

2

1 reference

16 August 2017

Matthew J Krasin

3

1 reference

16 August 2017

Jianrong Wu

4

1 reference

16 August 2017

Catherine A Billups

5

1 reference

16 August 2017

Najat C Daw

6

1 reference

16 August 2017

Sheri L Spunt

7

1 reference

16 August 2017

Bhaskar N Rao

8

1 reference

16 August 2017

Victor M Santana

9

1 reference

16 August 2017

Fariba Navid

10

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

110

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

375-384

1 reference

Treatment of Ewing sarcoma family of tumors: current status and outlook for the future

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Therapy for localized Ewing's sarcoma of bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22821

7 January 2021

Identifiers

DOI

10.1002/CNCR.22821

1 reference

16 August 2017

1 reference